Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.
Journal: The Journal of infectious diseases
Published: October 08, 2024
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Journal: The New England journal of medicine
Published: September 02, 2022
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: May 29, 2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: March 25, 2021
An Exposure-Response Perspective on the Clinical Dose of Pretomanid.
Journal: Antimicrobial agents and chemotherapy
Published: June 02, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
Journal: Antimicrobial agents and chemotherapy
Published: May 06, 2020
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Journal: The New England journal of medicine
Published: March 05, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: October 06, 2019
Daily Dosing for Bedaquiline in Patients with Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: March 10, 2019
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: March 01, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Journal: The Lancet. Respiratory medicine
Published: December 11, 2018
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
Journal: BMC pulmonary medicine
Published: November 16, 2018
Last Updated: 09/26/2026